ArticleEuropean journal of human genetics : EJHG2012
C1q enhances cone photoreceptor survival in a mouse model of autosomal recessive retinitis pigmentosa.
Article in European journal of human genetics : EJHG, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Progression of Geographic Atrophy in Age-related Macular Degeneration: AREDS2 Report Number 16.Ophthalmology · 2018Trial
- Safety and efficacy of AAV8-aflibercept in treating choroidal neovascularization via single-cell RNA sequencing.Molecular therapy. Methods & clinical development · 2025Article
- Linking Mitochondrial Gene Dysregulation to Immune Cell Shifts in Retinitis Pigmentosa.Molecular neurobiology · 2025Article
- Targeting Microglia to Treat Degenerative Eye Diseases.Frontiers in immunology · 2022Review
- Importance of Autoimmune Responses in Progression of Retinal Degeneration Initiated by Gene Mutations.Frontiers in medicine · 2021Review
- Modulation of three key innate immune pathways for the most common retinal degenerative diseases.EMBO molecular medicine · 2018Review
- Subretinal macrophages produce classical complement activator C1q leading to the progression of focal retinal degeneration.Molecular neurodegeneration · 2018Article
- Human cone visual pigment deletions spare sufficient photoreceptors to warrant gene therapy.Human gene therapy · 2013Article
- C1q induction and global complement pathway activation do not contribute to ALS toxicity in mutant SOD1 mice.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Article
- Complement component C1q regulates macrophage expression of Mer tyrosine kinase to promote clearance of apoptotic cells.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinitis pigmentosa (RP) is a degenerative retinal disease involving progressive loss of rod and cone photoreceptor function. It represents the most common form of registered blindness among the working aged populations of developed countries. Given the immense genetic heterogeneity associated with this disease, parameters influencing cone photoreceptor survival (preservation of daytime vision) that are independent of primary mutations are exceedingly important to identify from a therapeutic standpoint. Here we identify C1q, the primary component of the classical complement pathway, as a cone photoreceptor neuronal survival factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.